A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Trial details
- Registry ID
- NCT02436096
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Low dose cyclobenzaprine sublingual tablets
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaNCT02436096 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2016-09Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |